After having her large intestine removed, Caitlin Kimpton awaits two more major surgeries to help with her ulcerative colitis. Continue reading →

Nancy Ndure has raised 1,300 for charity as she raises awareness of colitis. (PA Real Life) A woman who hid her 'embarrassing' condition colitis from friends and family for a decade has now refused to stay silent anymore marking her newfound confidence and how far she's come with a skydive. Nancy Ndure, 27, from Telford in Shropshire, has lived with debilitating symptoms and the painful effects of surgeries due to the inflammatory bowel disease she's had since she was a teenager. Continue reading →

Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022 Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance study in moderate-to-severe ulcerative colitis (UC) selected by UEG as "one of the best abstracts" and eligible for an oral presentation at a moderated poster session Principal investigator Prof. Sverine Vermeire, M.D., Ph.D., to present Abivax's poster on October 10, 2022, at 11:54 a.m.- 12:00 (noon) CEST (5:54 a.m.-6:00 a.m. Continue reading →

Continuing anti-tumor necrosis factor (anti-TNF) therapy after 24 weeks of pregnancy is associated with a lower likelihood of relapse of inflammatory bowel disease (IBD) in pregnant women and fewer premature deliveries, according to a new report. In addition, the numbers of Cesarean sections, stillbirths, serious infections, and small or large weight for gestational size were similar in patients who continued or discontinued anti-TNF treatment after 24 weeks. "Discontinuation of anti-TNF treatment was associated with increased IBD activity and consequently with an increased rate of preterm birth," lead author Antoine Meyer, MD, PhD, a gastroenterologist at Assistance Publique-Hopitaux de Paris, France, and colleagues conclude. Continue reading →

John Hathaway never imagined itd take this long. But then again, the past eight years have been full of surprises. Continue reading →

New York, USA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Treg Cell-based Therapies Pipeline Landscape Analysis of 22+ Companies by DelveInsight Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T-cell (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-oncological disease indications. Continue reading →

ReportLinker The global enteral medical nutrition market is expected to reach US$ 11,726. 37 million by 2028 from US$ 7,803. 45 million in 2021; it is expected to grow at a CAGR of 6 Continue reading →